These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 25181339)
41. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. Gwak GY; Yoon JH; Shin CM; Ahn YJ; Chung JK; Kim YA; Kim TY; Lee HS J Cancer Res Clin Oncol; 2005 Oct; 131(10):649-52. PubMed ID: 16032426 [TBL] [Abstract][Full Text] [Related]
42. Upregulation of long non‑coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. Bai JG; Tang RF; Shang JF; Qi S; Yu GD; Sun C Mol Med Rep; 2018 Apr; 17(4):5328-5335. PubMed ID: 29393466 [TBL] [Abstract][Full Text] [Related]
43. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928 [TBL] [Abstract][Full Text] [Related]
44. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines. Yang J; Sontag D; Gong Y; Minuk GY Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415 [TBL] [Abstract][Full Text] [Related]
45. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells. Xu Y; Yao Y; Zhong X; Leng K; Qin W; Qu L; Cui Y; Jiang X Biochem Biophys Res Commun; 2018 Feb; 496(2):455-461. PubMed ID: 29337065 [TBL] [Abstract][Full Text] [Related]
46. EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. Moon A; Chin S; Kim HK; Kwak JJ; Koh ES; Kim YW; Jang KT Pathology; 2016 Jan; 48(1):35-40. PubMed ID: 27020207 [TBL] [Abstract][Full Text] [Related]
48. Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma. Jiao M; Ning S; Chen J; Chen L; Jiao M; Cui Z; Guo L; Mu W; Yang H Int J Oncol; 2020 Jun; 56(6):1455-1467. PubMed ID: 32236578 [TBL] [Abstract][Full Text] [Related]
49. Cholangiocarcinoma Prognosis Varies over Time Depending on Tumor Site and Pathology. Kaneko R; Sato Y; Kobayashi Y J Gastrointestin Liver Dis; 2018 Mar; 27(1):59-66. PubMed ID: 29557416 [TBL] [Abstract][Full Text] [Related]
50. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Xu Y; Wang Z; Jiang X; Cui Y Biomed Pharmacother; 2017 Aug; 92():17-23. PubMed ID: 28528181 [TBL] [Abstract][Full Text] [Related]
51. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979 [TBL] [Abstract][Full Text] [Related]
52. Abnormal expression of Forkhead Box J2 (FOXJ2) suppresses migration and invasion in extrahepatic cholangiocarcinoma and is associated with prognosis. Qiang Y; Wang F; Yan S; Zhang H; Zhu L; Chen Z; Tu F; Wang D; Wang G; Wang W; Chen Z Int J Oncol; 2015; 46(6):2449-58. PubMed ID: 25873280 [TBL] [Abstract][Full Text] [Related]
53. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma. Gu MJ; Choi JH J Clin Pathol; 2014 Mar; 67(3):229-34. PubMed ID: 24062361 [TBL] [Abstract][Full Text] [Related]
54. Role of the embryonic protein SOX2 in cholangiocarcinoma. Sun Q; Li J; Wang G; Xie Y Cell Biochem Biophys; 2014 Nov; 70(2):1311-6. PubMed ID: 24906237 [TBL] [Abstract][Full Text] [Related]
55. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148 [TBL] [Abstract][Full Text] [Related]
56. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589 [TBL] [Abstract][Full Text] [Related]
57. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Guo S; Liu HD; Liu YF; Liu L; Sun Q; Cui XJ Tumour Biol; 2015 Jan; 36(1):353-64. PubMed ID: 25262276 [TBL] [Abstract][Full Text] [Related]
58. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. Yeh CN; Pang ST; Wu RC; Chen TW; Jan YY; Chen MF Oncol Rep; 2009 Jan; 21(1):49-56. PubMed ID: 19082442 [TBL] [Abstract][Full Text] [Related]
59. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Zhou L; He XD; Cui QC; Zhou WX; Qu Q; Zhou RL; Rui JA; Yu JC Cancer Lett; 2008 Jun; 264(2):209-17. PubMed ID: 18334282 [TBL] [Abstract][Full Text] [Related]
60. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Boonjaraspinyo S; Wu Z; Boonmars T; Kaewkes S; Loilome W; Sithithaworn P; Nagano I; Takahashi Y; Yongvanit P; Bhudhisawasdi V Parasitol Int; 2012 Mar; 61(1):145-50. PubMed ID: 21777692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]